Novo’s Nash play takes shape
Novo Nordisk Snags FDA Approval for Oral Type 2 Diabetes Drug
Lilly’s Trulicity cuts heart risks by 12%. Is it enough to fend off semaglutide?
Novo Nordisk’s Ozempic Continues to Show Superiority in Diabetes Control
With Obesity on the Continued Rise in the U.S., More Anti-Obesity Drugs Are Heading for the Market
Novo hopes slimmed-down bet can still win in obesity
Novo Nordisk’s semaglutide is headed toward a Lilly showdown. Will Novo speed it up?
Novo’s next big diabetes bet heads to regulators
Lilly’s under-pressure Trulicity scores with first-of-its-kind cardio outcomes win
Novo Nordisk boosts its GLP-1 score with yet more evidence for crucial semaglutide pill
Months after partnering with Sanofi on infectious diseases, Germany-based Evotec has formed another significant partnership with Novo Nordisk. The two companies will combine their forces to develop treatments for diabetes, nonalcoholic steatohepatitis (NASH) and other diseases. Evotec … Continue Reading Evotec and Novo Nordisk Ink Deal to Develop Drugs for Obesity and Diabetes
The approval case for Novo Nordisk’s oral GLP-1 diabetes candidate keeps on building, this time with new data in patients with kidney troubles. Monday, the Danish drugmaker said that in a phase … Continue Reading Novo data buttress its oral semaglutide case, this time in kidney-impaired patients
Dive Brief: Against a backdrop of intense market competition, Novo Nordisk has rolled out a direct-to-consumer campaign for Ozempic, its once-weekly, injectable Type 2 diabetes medication. Set to the tune … Continue Reading With diabetes competitive as ever, Novo launches Ozempic DTC campaign
What Did Ian Read Learn From Trump? Pfizer Inc. CEO Ian Read may have as much insight as anyone in the pharma world into US President Donald Trump’s thinking on drug … Continue Reading Pharma Q2 Results Preview: Pfizer, Teva, Shire, Sanofi And Novo Nordisk